Loading
SCTB14 is an experimental investigational agent whose form is not stated in the registry from Sinocelltech in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.
SCTB14 is an investigational agent whose form is not stated in the registry developed by Sinocelltech. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: SCTB14 is administered at selected dose by intravenous infusion on Day 1 of each 3-week cycle. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07362459 (A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer), in non-small-cell lung cancer. The largest, NCT07362459, plans to enrol 246 participants with primary completion expected 2027-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.SCTB14 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"SCTB14" OR ABSTRACT:"SCTB14") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SCTB14, not a curated reading list.
Shares Sinocelltech and the tag pipeline.
Shares Sinocelltech and the tag pipeline.
Shares Sinocelltech and the tag pipeline.
Shares Sinocelltech and the tag pipeline.
Shares Sinocelltech, Non-small-cell lung cancer and the tag pipeline.
Shares Sinocelltech and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.